Metropolitan Life Insurance Company (MetLife)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,921
| Closed | -$341K | – | 2209 |
|
|
2024
Q1 | $341K | Sell |
4,921
-472
| -9% | -$32.4K | 0.01% | 552 |
|
|
2023
Q4 | $386K | Hold |
5,393
| – | – | 0.02% | 521 |
|
|
2023
Q3 | $281K | Buy |
5,393
+277
| +5% | +$16.1K | 0.01% | 566 |
|
|
2023
Q2 | $324K | Buy |
5,116
+175
| +4% | +$10.9K | 0.02% | 532 |
|
|
2023
Q1 | $268K | Sell |
4,941
-804
| -14% | -$38.9K | 0.01% | 577 |
|
|
2022
Q4 | $304K | Buy |
5,745
+223
| +4% | +$11.2K | 0.01% | 565 |
|
|
2022
Q3 | $257K | Hold |
5,522
| – | – | 0.01% | 593 |
|
|
2022
Q2 | $315K | Buy |
5,522
+388
| +8% | +$22K | 0.01% | 555 |
|
|
2022
Q1 | $314K | Sell |
5,134
-13,228
| -72% | -$687K | 0.01% | 632 |
|
|
2021
Q4 | $961K | Sell |
18,362
-1,260
| -6% | -$52.9K | 0.01% | 995 |
|
|
2021
Q3 | $732K | Buy |
19,622
+95
| +0.5% | +$3.3K | 0.01% | 1182 |
|
|
2021
Q2 | $797K | Buy |
19,527
+1,180
| +6% | +$43.6K | 0.01% | 1179 |
|
|
2021
Q1 | $623K | Sell |
18,347
-715
| -4% | -$24.8K | 0.01% | 1284 |
|
|
2020
Q4 | $606K | Hold |
19,062
| – | – | 0.01% | 1240 |
|
|
2020
Q3 | $489K | Buy |
19,062
+2,610
| +16% | +$59.5K | 0.01% | 1230 |
|
|
2020
Q2 | $422K | Hold |
16,452
| – | – | 0.01% | 1339 |
|
|
2020
Q1 | $253K | Buy |
16,452
+3,585
| +28% | +$77.9K | 0.01% | 1456 |
|
|
2019
Q4 | $441K | Sell |
12,867
-1,149
| -8% | -$13.8K | 0.01% | 1406 |
|
|
2019
Q3 | $105K | Hold |
14,016
| – | – | ﹤0.01% | 2280 |
|
|
2019
Q2 | $182K | Hold |
14,016
| – | – | ﹤0.01% | 1949 |
|
|
2019
Q1 | $171K | Hold |
14,016
| – | – | ﹤0.01% | 2010 |
|
|
2018
Q4 | $160K | Hold |
14,016
| – | – | ﹤0.01% | 1954 |
|
|
2018
Q3 | $304K | Hold |
14,016
| – | – | 0.01% | 1712 |
|
|
2018
Q2 | $248K | Hold |
14,016
| – | – | ﹤0.01% | 1801 |
|
|
2018
Q1 | $295K | Buy |
14,016
+766
| +6% | +$14.9K | ﹤0.01% | 1628 |
|
|
2017
Q4 | $192K | Sell |
13,250
-11,914
| -47% | -$184K | ﹤0.01% | 1935 |
|
|
2017
Q3 | $397K | Hold |
25,164
| – | – | ﹤0.01% | 1837 |
|
|
2017
Q2 | $313K | Hold |
25,164
| – | – | ﹤0.01% | 2037 |
|
|
2017
Q1 | $409K | Hold |
25,164
| – | – | ﹤0.01% | 1794 |
|
|
2016
Q4 | $380K | Hold |
25,164
| – | – | ﹤0.01% | 1910 |
|
|
2016
Q3 | $383K | Hold |
25,164
| – | – | ﹤0.01% | 1873 |
|
|
2016
Q2 | $977K | Buy |
25,164
+6,491
| +35% | +$233K | 0.01% | 1268 |
|
|
2016
Q1 | $519K | Hold |
18,673
| – | – | ﹤0.01% | 1558 |
|
|
2015
Q4 | $1M | Buy |
18,673
+3,517
| +23% | +$177K | 0.01% | 1186 |
|
|
2015
Q3 | $607K | Buy |
15,156
+40
| +0.3% | +$1.3K | ﹤0.01% | 1505 |
|
|
2015
Q2 | $483K | Buy |
+15,116
| New | +$383K | ﹤0.01% | 1771 |
|
|
2015
Q1 | – | Sell |
-17,408
| Closed | -$307K | – | 2467 |
|
|
2014
Q4 | $307K | Sell |
17,408
-1,172
| -6% | -$18.3K | ﹤0.01% | 2113 |
|
|
2014
Q3 | $255K | Hold |
18,580
| – | – | ﹤0.01% | 2202 |
|
|
2014
Q2 | $313K | Buy |
+18,580
| New | +$307K | ﹤0.01% | 2167 |
|
Other funds holding ITCI
WA
ACA
BG
Metropolitan Life Insurance Company (MetLife)'s ITCI Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 4,921 shares — an estimated $341K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in ITCI in Q2 2014 and held it in 39 quarters. The position peaked at $1M in Q4 2015. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 4,921 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $341K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 39 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Intra-Cellular Therapies Inc. position peaked at $1M in Q4 2015.
- 376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.